CGEM Cullinan Therapeutics, Inc.
$20.59▼ -1.95%
Healthcare
Other
After hours
$20.89▲ +1.46%
Sep 11, 7:30 PM ET
Volume 1.09M
Avg Volume (10D) 722.5K
Key Metrics & Fundamentals
Market Cap
$1.27B
P/E Ratio
–
Div Yield
–%
52W Range
5.68 - 23.19
% vs 50 MA
6.31%
% vs 200 MA
38.47%
RSI-14
48.1
MACD Histogram
-0.3200
Beta (1Y vs SPY)
1.35
Free Cash Flow
-$38.22M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$57.18M
COGS
–
Operating Exp
$57.25M
Operating Income
-$57.25M
EBIT
-$57.25M
Pretax Income
-$53.70M
Net Income
-$53.70M
EPS (Diluted)
-0.81
Price & Volume History
Loading chart…
Recent News
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
GlobeNewswire · Sep 10, 2026 5:00 PM
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer
Business Wire · Aug 19, 2026 4:03 PM
UBS Adjusts Cullinan Therapeutics Price Target to $27 From $24, Maintains Buy Rating
MT Newswires · Aug 17, 2026 2:05 PM
Sector Update: Healthcare Stocks Softer in Afternoon Trading
MT Newswires · Aug 13, 2026 5:50 PM
Sector Update: Healthcare Stocks Advance Pre-Bell Thursday
MT Newswires · Aug 13, 2026 1:13 PM
New Taiho, Cullinan data heats up lung cancer drug battle
BioPharma Dive · Aug 13, 2026 12:05 PM
Wedbush Adjusts PT on Cullinan Therapeutics to $42 From $39, Maintains Outperform Rating
MT Newswires · Aug 13, 2026 11:45 AM
Cullinan Therapeutics Says Phase 3 Trial of Experimental Lung Cancer Drug Met Primary Endpoint
MT Newswires · Aug 13, 2026 8:11 AM
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Business Wire · Aug 12, 2026 11:30 PM
The Bull Case For Cullinan Therapeutics (CGEM) Could Change Following FDA-Backed Phase 2 CLN-049 Trial
Simply Wall St. · Aug 7, 2026 12:16 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See CGEM's money flow as a full page
Social Sentiment
Avg +0.73 · 3 posts
DDNewsDiscussionPriceTargetCgem
r/wallstreetbets · Oct 26, 2025
Significant upside potential cited by analysts and positive discussion around clinical trial catalysts.
positive
+0.80
DDPriceTargetNewsCgem
r/wallstreetbets · Oct 26, 2025
The post highlights positive aspects like analyst ratings, insider activity, and upcoming trials.
positive
+0.80
NewsTradePriceTargetDDCgem
r/wallstreetbets · Oct 26, 2025
The post highlights a purchase by a significant investor and a positive analyst price target, indicating bullish sentiment.
positive
+0.60
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.